Collplant Holdings (CLGN) has released an update.
CollPlant Biotechnologies has achieved a significant milestone by successfully bio-printing 200cc commercial-size regenerative breast implants, showing promising pre-clinical results including tissue regeneration and neovascularization without adverse reactions. These advancements in their proprietary non-animal derived recombinant human collagen (rhCollagen) technology could revolutionize reconstructive and aesthetic procedures by offering a safer alternative to traditional synthetic implants. The company anticipates further results from ongoing animal studies in late 2024 and early 2025, paving the way for potential market leadership in regenerative medicine.
For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.
